TABLE 3.
Ratio of geometric least squares mean and 90% CI estimates of bempedoic acid and ESP15228 pharmacokinetic parameters
| Parameter | Treatment comparison a | Bempedoic acid | ESP15228 | ||
|---|---|---|---|---|---|
| Geometric LS mean ratio | 90% CI | Geometric LS mean ratio | 90% CI | ||
| Cmax, μg/ml | B/A | 1.398 | 1.059–1.845 | 1.377 | 1.095–1.732 |
| C/A | 0.952 | 0.697–1.299 | 1.363 | 1.054–1.762 | |
| D/A | 1.198 | 0.878–1.635 | 1.458 | 1.127–1.885 | |
| AUClast, μg•h/ml | B/A | 1.495 | 1.045–2.141 | 1.667 | 1.121–2.479 |
| C/A | 2.184 | 1.461–3.265 | 2.620 | 1.679–4.089 | |
| D/A | 2.233 | 1.493–3.339 | 2.669 | 1.710–4.166 | |
| AUCinf, μg•h/ml | B/A | 1.501 | 1.049–2.149 | 1.673 | 1.126–2.486 |
| C/A | 2.187 | 1.463–3.270 | 2.588 | 1.660–4.034 | |
| D/A | 2.228 | 1.490–3.331 | 2.623 | 1.683–4.089 | |
Abbreviations: AUCinf, area under the concentration‐time curve calculated from time 0 to infinity; AUClast, area under the concentration‐time curve from time 0 to time of last measurable concentration; CI, confidence interval; Cmax, maximum observed concentration; eGFR, estimated glomerular filtration rate; LS, least squares.
a
A = normal renal function (eGFR ≥ 90 ml/min); B = mild renal impairment (eGFR 60–<90 ml/min); C = moderate renal impairment (eGFR 30–<60 ml/min); D = severe renal impairment (eGFR <30 ml/min).